Skip to content

    Insight Molecular Diagnostics (IMDX) stock price & financials

    View IMDX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+66.5% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $115.0K
    $1.49M
    $2.14M
    $518.0K
    $260.0K
    +126.1%
    $1.14M
    -23.4%
    $32.0K
    -98.5%
    $239.0K
    -53.9%
    Weakening
    Operating Profit
    -$13.52M
    -$33.63M
    -$6.80M
    -$9.84M
    -$11.05M
    +18.3%
    -$23.43M
    +30.3%
    -$4.41M
    +35.1%
    -$11.40M
    -15.9%
    Strengthening
    Net Profit
    -$13.49M
    -$33.51M
    -$6.67M
    -$9.74M
    -$10.85M
    +19.6%
    -$22.95M
    +31.5%
    -$4.29M
    +35.7%
    -$11.26M
    -15.6%
    Strengthening
    EPS
    $-0.98
    $-0.26
    $-0.30
    $-0.34
    +65.3%
    $-0.12
    +53.8%
    $-0.31
    -3.3%
    Strengthening
    Other Income
    $22.0K
    $116.0K
    $128.0K
    $100.0K
    $194.0K
    +781.8%
    $480.0K
    +313.8%
    $123.0K
    -3.9%
    $142.0K
    +42.0%
    Strengthening
    Interest
    Depreciation
    Profit before Tax
    -$13.49M
    -$33.51M
    MarginsOPM
    -11752.2%
    -2262.9%
    -318.0%
    -1900.0%
    -4249.2%
    +63.8%
    -2057.5%
    +9.1%
    -13790.6%
    -4236.5%
    -4770.7%
    -151.1%
    Weakening
    Tax
    0.0%
    0.0%
    ReturnsROIC
    63.2%
    156.8%
    31.2%
    45.6%
    50.8%
    -19.6%
    107.4%
    -31.5%
    20.1%
    -35.7%
    52.7%
    +15.6%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$8.03M$22.07M$7.14M$32.95M$19.99M$9.43M$8.64M$11.58M$17.76M
    Short-Term Investments
    Total Current Assets$8.64M$22.96M$9.23M$39.14M$25.54M$10.70M$11.76M$15.31M$20.54M
    Net PP&E$614.0K$6.46M$7.83M$10.63M$12.21M$4.71M$6.32M$6.43M$6.00M
    Goodwill$9.19M$18.68M
    Intangibles$15.01M$61.72M$61.63M$56.59M$14.61M$0
    Total Assets$9.52M$39.86M$55.42M$159.56M$100.09M$74.89M$35.08M$25.76M$29.44M
    LiabilitiesTotal Current Liabilities$5.56M$4.44M$9.00M$14.12M$12.11M$7.19M$7.28M$12.07M$10.29M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases
    Total Liabilities$6.09M$9.02M$21.94M$94.35M$60.50M$49.30M$47.35M$57.22M$50.74M
    EquityCommon Stock & APIC$74.74M$124.58M$157.16M$252.95M$294.93M$310.30M$338.24M$369.21M$394.94M
    Retained Earnings-$71.32M-$93.75M-$123.68M-$187.77M-$260.68M-$289.88M-$350.54M-$400.76M-$416.31M
    Total Equity$3.42M$30.84M$33.48M$65.22M$34.29M$20.47M-$12.27M-$31.46M-$21.30M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$11.65M-$19.71M-$25.98M-$35.94M-$45.57M-$23.32M-$20.69M-$22.18M-$27.08M
    Cash from Investing-$31.0K-$12.41M-$11.75M-$13.96M-$4.34M-$932.0K-$512.0K-$3.19M-$3.92M
    Cash from Financing$12.11M$47.87M$22.80M$78.36M$35.81M$12.19M$20.43M$28.07M$23.76M
    SummaryCapital Expenditure-$31.0K-$918.0K-$1.23M-$2.25M-$4.34M-$281.0K-$516.0K-$3.19M-$3.92M
    Free Cash Flow-$11.68M-$20.63M-$27.21M-$38.19M-$49.91M-$23.61M-$21.20M-$25.37M-$31.00M
    FCF Margin-2237.4%-1737.4%-5209.6%-1570.6%-1127.3%-625.6%-1856.2%

    Ratios